Browsing Tag
CSL Behring
6 posts
uniQure (QURE, NASDAQ) targets Q3 BLA after FDA’s Huntington’s reversal
The FDA spent months blocking uniQure's Huntington's gene therapy. Now it wants the filing in Q3. QURE doubled, but approval is still unwon.
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead
CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
CSL Behring bags Hemgenix EC approval for treatment of Hemophilia B
German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its…
CSL Behring gets Hemgenix FDA approval for hemophilia B
CSL Behring, a US-based biotechnology company, has received approval for its Hemgenix (etranacogene dezaparvovec-drlb) from the US Food…